RJA
KURA icon

Raymond James & Associates’s Kura Oncology KURA Stock Holding History

Raymond James & Associates’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,961
Closed -$207K – 3910
2023
Q1 		$207K Buy
16,961
+1,272
+8% +$15.9K ﹤0.01% 3475
2022
Q4 		$195K Sell
15,689
-1,586
-9% -$23.1K ﹤0.01% 3467
2022
Q3 		$236K Sell
17,275
-277
-2% -$4.27K ﹤0.01% 3338
2022
Q2 		$322K Sell
17,552
-46
-0.3% -$662 ﹤0.01% 3185
2022
Q1 		$283K Buy
17,598
+2,757
+19% +$39.8K ﹤0.01% 3453
2021
Q4 		$208K Sell
14,841
-2,998
-17% -$48.6K ﹤0.01% 3675
2021
Q3 		$334K Sell
17,839
-452
-2% -$8.52K ﹤0.01% 3343
2021
Q2 		$381K Sell
18,291
-36
-0.2% -$894 ﹤0.01% 3269
2021
Q1 		$518K Sell
18,327
-956
-5% -$30.2K ﹤0.01% 2986
2020
Q4 		$630K Sell
19,283
-655
-3% -$23K ﹤0.01% 2657
2020
Q3 		$611K Buy
19,938
+1,028
+5% +$22.7K ﹤0.01% 2488
2020
Q2 		$308K Buy
18,910
+1,628
+9% +$23.5K ﹤0.01% 2904
2020
Q1 		$172K Sell
17,282
-1,151
-6% -$13.2K ﹤0.01% 3083
2019
Q4 		$253K Sell
18,433
-236
-1% -$3.5K ﹤0.01% 3187
2019
Q3 		$283K Sell
18,669
-226
-1% -$4.02K ﹤0.01% 3047
2019
Q2 		$372K Sell
18,895
-4,595
-20% -$76.3K ﹤0.01% 2867
2019
Q1 		$390K Buy
23,490
+2,676
+13% +$41.2K ﹤0.01% 2831
2018
Q4 		$292K Sell
20,814
-4,824
-19% -$63.9K ﹤0.01% 2883
2018
Q3 		$449K Buy
+25,638
New +$492K ﹤0.01% 2783

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Raymond James & Associates's KURA Position: Q2 2023 in Review

Raymond James & Associates sold out of Kura Oncology (KURA) in Q2 2023, closing a stake of 16,961 shares — an estimated $207K sold.

Raymond James & Associates first reported a position in KURA in Q3 2018 and held it in 19 quarters. The position peaked at $630K in Q4 2020. 148 funds tracked by Wall St. Rank hold KURA as of Q2 2023.

  • Raymond James & Associates reported no remaining Kura Oncology position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 16,961 Kura Oncology shares in Q2 2023, an estimated $207K.
  • Raymond James & Associates first reported a position in Kura Oncology in Q3 2018 and held it in 19 quarters.
  • Raymond James & Associates's Kura Oncology position peaked at $630K in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.